Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
34
Journal Issue
1
Pages
59-67
Date Issued
2019
Author(s)
Yeo Y.H.
Hsu C.-C.
Lee C.-C.
Ho H.J.
Lin J.-T.
Wu C.-Y.
Taiwan Gastrointestinal Disease
Helicobacter Consortium
Abstract
Background and Aim: The eradication rate of Helicobacter pylori (H. pylori) has been declining over the past decades. A rescue plan is needed for increasing populations with treatment failure. However, the optimum second-line eradication regimen remains inconclusive. We conducted a network meta-analysis to assess the comparative effectiveness of second-line H. pylori eradication therapies and determine the optimum regimen. Methods: We searched electronic databases from January 2005 to February 2018 for randomized controlled trials assessing the effectiveness of second-line regimens in patients with persistent H. pylori infection after first-line treatment. Bayesian network meta-analysis was performed to combine the direct and indirect evidence and to investigate the rank order of second-line therapies. We also appraised the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation guidance. Results: Twenty-six trials with 3628 participants who received second-line eradication therapy were identified. All regimens showed pooled eradication rates < 90%. Compared with 7-day triple therapy, quinolone-based (odds ratio [OR] 4.29, 95% credible interval [CrI] 1.67–12.12, surface under the cumulative ranking [SUCRA] 0.95), non-quinolone-based bismuth-containing quadruple therapies for 10 days or more (OR 2.25, 95% CrI 1.10–4.62, SUCRA 0.78), and sequential therapy (OR 2.91, 95% CrI 1.16–7.65, SUCRA 0.66) showed significantly higher effectiveness. Overall, regimens with longer duration demonstrated higher eradication rates but higher rates of adverse events. More adverse events were reported in those patients treated with concomitant therapy. Conclusions: Quinolone-based bismuth-containing quadruple therapies for 10 days or more are the optimum second-line regimens for H. pylori eradication.
SDGs
Publisher
Blackwell Publishing
Type
review